孟鲁司特钠联合布地奈德治疗小儿支原体肺炎所致慢性咳嗽的临床效果观察

Observation on clinical effect of montelukast sodium combined with budesonide in treatment of chronic cough caused by mycoplasma pneumonia in children

目的评价孟鲁司特钠、布地奈德联合应用治疗小儿支原体肺炎所致慢性咳嗽的临床效果,为进一步改善患儿临床治疗效果的药物治疗方案提供理论依据。方法将2015年6月-2018年5月梧州市人民医院儿科收治88例支原体肺炎感染所致慢性咳嗽患儿随机分为对照组和治疗组各44例,予以对照组患儿布地奈德治疗,予以治疗组患儿孟鲁司特钠、布地奈德联合治疗,比较两组患儿治疗前、后的咳嗽积分、血清CRP水平及治疗总有效率和不良反应发生率。结果治疗前两组患儿咳嗽积分、血清CRP水平比较差异均无统计学意义(P>0.05);治疗后治疗组患儿咳嗽积分、血清CRP水平均低于对照组患儿,治疗总有效率95.45%高于对照组患儿的79.55%,两组差异均有统计学意义(P<0.05)。不良反应发生率两组比较差异无统计学意义(P>0.05)。结论孟鲁司特钠与布地奈德联合应用治疗小儿支原体肺炎所致慢性咳嗽能够获得优于布地奈德单一治疗的临床效果,且不会明显增加患儿的用药风险,具有推广应用价值。

Objective To evaluate the clinical effect of montelukast sodium combined with budesonide in treatment of chronic cough caused by mycoplasma pneumonia in children,provide a theoretical basis for drug therapy of further improving clinical effect.Methods From June 2015 to May 2018,88 children with chronic cough caused by mycoplasma pneumonia treated in Department of Pediatrics,Wuzhou People's Hospital were selected and randomly divided into control group and treatment group,44 children in each group.The children in control group were treated by budesonide,the children in treatment group were treated by montelukast sodium combined with budesonide.Coughing scores and serum CRP levels before and after treatment,the total effective rates,and the incidence rates of adverse reactions in the two groups were compared.Results Before treatment,there was no statistically significant difference in coughing score and serum CRP level between the two groups(P>0.05).After treatment,coughing score and serum CRP level in treatment group were statistically significantly lower than those in control group,the total effective rate in treatment group was 95.45%,which was statistically significantly higher than that in control group(79.55%)(P<0.05).There was no statistically significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of montelukast sodium combined with budesonide in treatment of chronic cough caused by mycoplasma pneumonia in children is superior to single application of budesonide,and the combined therapy will not significantly increase the risk of drug use in children,which is worthy of promotion and application.